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Introduction: The objective of this work was to evaluate the efficacy of placenta-derived mesenchymal stem cell
(MSC) therapy in a mouse model of myocardial infarction (MI). Since MSCs can be obtained from two different
regions of the human term placenta (chorionic plate or villi), cells obtained from both these regions were compared
so that the best candidate for cell therapy could be selected.
Methods: For the in vitro studies, chorionic plate MSCs (cp-MSCs) and chorionic villi MSCs (cv-MSCs) were
extensively characterized for their genetic stability, clonogenic and differentiation potential, gene expression, and
immunophenotype. For the in vivo studies, C57Bl/6 mice were submitted to MI and, after 21 days, received weekly
intramyocardial injections of cp-MSCs for 3 weeks. Cells were also stably transduced with a viral construct expressing
luciferase, under the control of the murine stem cell virus (MSCV) promoter, and were used in a bioluminescence assay.
The expression of genes associated with the insulin signaling pathway was analyzed in the cardiac tissue from cp-MSCs
and placebo groups.
Results: Morphology, differentiation, immunophenotype, and proliferation were quite similar between these cells.
However, cp-MSCs had a greater clonogenic potential and higher expression of genes related to cell cycle progression
and genome stability. Therefore, we considered that the chorionic plate was preferable to the chorionic villi for the
isolation of MSCs. Sixty days after MI, cell-treated mice had a significant increase in ejection fraction and a reduction in
end-systolic volume. This improvement was not caused by a reduction in infarct size. In addition, tracking of cp-MSCs
transduced with luciferase revealed that cells remained in the heart for 4 days after the first injection but that the
survival period was reduced after the second and third injections. Quantitative reverse transcription-polymerase chain
reaction revealed similar expression of genes involved in the insulin signaling pathway when comparing cell-treated
and placebo groups.
Conclusions: Improvement of cardiac function by cp-MSCs did not require permanent engraftment and was not
mediated by the insulin signaling pathway.* Correspondence: carvalhoab@biof.ufrj.br
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Multipotent mesenchymal stem cells (MSCs) are an at-
tractive source of stem cells for tissue repair. They are
known for their immunomodulatory properties [1] and
ability to differentiate into several mesenchymal lineages,
including adipocytes, osteocytes, and chondrocytes [2],
when submitted to specific culture conditions. They
have been identified in various organs [3-5], but fre-
quency and differentiation potential of adult MSCs are
dependent upon the age of the donor [6,7]. Moreover,
invasive procedures may be required to obtain them.
On the other hand, fetal MSCs can be derived from
the fetus or from extra-embryonic structures that are of
fetal origin [8]. These structures are discarded after birth
and therefore are easy to obtain and available in large
scale, which makes them interesting sources for the
isolation and banking of stem cell populations. In this
context, MSCs phenotypically similar to bone marrow
MSCs have been isolated from various extra-embryonic
structures, including amniotic fluid [9,10], Wharton’s
jelly [11], amniotic and chorionic membrane [12], and
human placenta, which has been used by many authors
for the isolation of stem cells (Additional file 1).
Several reports have shown that it is possible to extract
MSCs from both the chorionic villi (cv) [13-22] and chori-
onic plate (cp) [22-27] of the term placenta. However, it
remains undetermined whether there is any difference be-
tween cv-MSCs and cp-MSCs or which placental region is
a better source of extra-embryonic MSCs. In the present
study, we described and compared the isolation and
phenotypic and functional characterization of cell popula-
tions derived from these regions of the human term pla-
centa to investigate which would be a preferable source of
MSCs for cell therapy.
In addition, cell therapy using MSCs has emerged as a
promising alternative to treat chronic diseases. This is
especially important in the case of ischemic heart disease
and congestive heart failure, which are major causes of
morbidity and mortality throughout the world and im-
pose a significant economic burden on most health sys-
tems [28]. Initially, regeneration of cardiac muscle was
thought to be the main mechanism involved in the im-
provement of cardiac function promoted by cell therapy
[29-32]. However, this capacity has been challenged, es-
pecially in the case of adult stem cells [33-37]. In this
work, we evaluated the role of placenta-derived MSCs in
the treatment of cardiac dysfunction post-myocardial in-
farction (MI) in immunocompetent mice.
Materials and methods
Isolation and culture of human placenta-derived mesenchymal
stem cells
Full-term human placentas (38 to 40 weeks of gestation;
n = 16) were obtained after maternal informed consent.All experiments were approved by our local institutional
review board (Hospital Universitário Clementino Fraga
Filho, Universidade Federal do Rio de Janeiro, Rio de
Janeiro, Brazil). Once the amniotic membrane was manu-
ally separated and discarded, the harvested pieces of chori-
onic plate and chorionic villi were mechanically minced
and enzymatically digested with 100 and 200 U/mL of type
II collagenase, respectively (Roche, Basel, Switzerland), for
5 hours at 37°C with orbital shaking. Both single-cell sus-
pensions were filtered through a 100-μm cell strainer (BD
Biosciences, San Jose, CA, USA) to eliminate undigested
fragments, and the cells were collected by centrifugation
at 670g for 15 minutes. Mononuclear cells were recovered
by Ficoll density gradient (Ficoll-Paque PLUS-1077 g/mL;
Amersham Bioscience, now part of GE Healthcare, Little
Chalfont, Buckinghamshire, UK) after centrifugation at
400g for 30 minutes at room temperature. Cells were
suspended in expansion medium constituted by alpha
modified essential medium (αMEM) (LGC Biotecnologia,
São Paulo Brazil) supplemented with 15% fetal bovine
serum (FBS) (Gibco, now part of Invitrogen Corporation,
Carlsbad, CA, USA) and 1% penicillin/streptomycin (Gibco),
plated at a density of 5 × 105 cells per centimeter
squared, and incubated at 37°C in a 5% CO2 incubator.
Cells were allowed to adhere for 2 days, and the non-
adherent cells were washed away during medium changes.
Third-passage cells were used in all experiments, unless
otherwise specified.
Fibroblast colony-forming unit assay
Fibroblast colony-forming units (CFU-F) assays were
performed on freshly isolated cells from chorionic plate
(n = 6) and chorionic villi (n = 5). Each well of a six-well
plate (Corning Costar, Tewksbury MA, USA) received
105 freshly isolated cells, which were cultured in expan-
sion medium supplemented with 10−5 M of hydrocorti-
sone (Strides Arcolab Limited, Bangalore, Karnataka).
After a 15-day period, colonies were fixed with methanol
PA (Vetec Quimica Fina, now part of Sigma-Aldrich, St.
Louis, MO, USA) for 5 minutes at room temperature
and counted after Giemsa staining (Proquimios, Rio de
Janeiro, Brazil).
Flow cytometry
For immunophenotypic analysis, third-passage cp-MSCs
(n = 5) and cv-MSCs (n = 4) were dissociated and sus-
pended in blocking solution containing cold phosphate-
buffered saline (PBS) supplemented with 5% FBS for 20
minutes. All antibodies, except CD133 (Miltenyi Biotec,
Bergisch Gladbach, Germany), were purchased from BD
Biosciences.
The following antibodies conjugated with fluorescein
isothiocyanate (FITC), phycoerythrin (PE), peridinin
chlorophyll protein (PerCP), allophycocyanin (APC), or
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2D1), CD34 (clone 8Y12), CD44 (clone L178), CD117
(clone 104D2), CD31 (clone WM59), CD133 (clone
29C3), CD166 (clone 3A6), CD54 (clone HA58), CD146
(clone P1H12), CD14 (clone MΦP9), CD19 (clone 4G7),
HLA-DR (clone TU36), CD73 (clone AD2) and CD90
(clone 5E10), and CD105 (clone 266). Cells were stained
in accordance with the instructions of the manufacturer,
and 7 aminoactinomyocin D (7AAD) was added to ex-
clude dead cells.
After 30 minutes of incubation at 4°C, cells were
washed with PBS, centrifuged at 400g for 3 minutes, and
suspended in PBS for acquisition. Samples were acquired
in a BD FACSCanto flow cytometer (BD Biosciences),
and the resulting data were analyzed by using FACSDiva
software version 6.1.1 (BD Biosciences).
Multipotent differentiation assays
All differentiation reagents were purchased from Sigma-
Aldrich, unless otherwise specified. Media were changed
three times a week, and no passages were made during
the differentiation protocols. Non-induced control sam-
ples were submitted to the same procedures but were
maintained in expansion medium.
Adipogenic differentiation was induced by culturing
cp-MSCs (n = 3) and cv-MSCs (n = 3) for 21 days in
Dulbecco’s modified Eagle’s medium-high glucose
(DMEM-HG) supplemented with 10% FBS, 1% penicil-
lin/streptomycin, 10−6 M dexamethasone, 10 μg/mL hu-
man insulin, 0.5 μM isobutylemethylxanthine, and 200
μM indomethacin. Cells were fixed with formalin for 30
minutes at room temperature, and cytoplasmic lipid
droplets were stained with 0.2% Oil Red O.
Osteogenic differentiation was performed by culturing
cp-MSCs (n = 3) and cv-MSCs (n = 3) in DMEM-HG,
10% FBS, 1% penicillin/streptomycin, 10−6 M dexa-
methasone, 10 mM β-glycerolphosphate, and 0.5 μM as-
corbic phosphate acid for 21 days. Cells were fixed with
formalin for 30 minutes at room temperature, and extra-
cellular calcium deposits were stained after 30 minutes
of incubation with 1% Alizarin Red in water.
Chondrogenic differentiation was performed under
micromass conditions by using a STEMPRO® Chondro-
genesis Differentiation kit (catalog A10071-01; Invitro-
gen Corporation) in accordance with the guidelines of
the manufacturer. Briefly, micromasses were generated
by using approximately 8 × 104 cp-MSCs (n = 3) and cv-
MSCs (n = 3) seeded in 5-μL droplets of cell solution
and cultured for 2 hours under high-humidity condi-
tions. Micromasses were subsequently cultured in chon-
drogenesis medium (Invitrogen Corporation) for 21
days. The pellets were fixed with 4% paraformaldehyde
for 30 minutes at room temperature and embedded in
paraffin. The presence of proteoglycans, characteristic ofchondrocytes, was evaluated after staining with 1%
Alcian Blue in 3% acetic acid solution for 30 minutes.
Counterstaining was performed with Nuclear Fast Red.
Population doubling time
Growth kinetics of cp-MSCs (n = 3) and cv-MSCs (n = 5)
was assessed by estimating population doubling time
(PDT). Cells (104) were plated in 35-mm cell culture
dishes with a 2-mm grid (Nalge Nunc International,
Penfield, NY, USA) in expansion medium. Cells were
counted daily, and the number of cells per millimeter
squared was calculated. These values were used to build a
cells per millimeter squared versus time plot. Appling a base
2 logarithm in the cells per millimeter squared axis, we were
able to perform a linear regression, in which the inverse of
the angular coefficient α was used to calculate PDT.
Karyotype analysis
For detection of aneuploidy, chromosome preparations
were performed in cp-MSCs (n = 4) and cv-MSCs (n = 3).
Cells were arrested in metaphase with 1.2 μg/mL of colce-
mide (Sigma-Aldrich), dissociated from culture flasks with
trypsin-EDTA (Gibco), and incubated with hypotonic so-
lution (KCl 75 mM) (Vetec Quimica Fina) for 15 minutes
at 37°C. Cells were collected after centrifugation (200g for
10 minutes) and fixed with a methanol-acetic acid solution
(3:1). Chromosome spreads were obtained by pipetting
suspension drops onto clean glass slides. Metaphase cells
were GTG-banded by using Giemsa, and 20 metaphases
were karyotyped for each sample.
Animals
Experiments were performed in 8- to 10-week-old female
immunocompetent C57Bl/6 mice (20.5 to 25.0 grams). All
experiments were performed in conformity with the Guide
for the Care and Use of Laboratory Animals (National
Institutes of Health) and were approved by the Committee
on the Ethics of Animal Use of the Federal University of
Rio de Janeiro under number IBCCF 026. Mice were
housed at a controlled temperature (23°C) with a 12:12-
hour light-dark cycle and received standard mouse chow
and water ad libitum.
Myocardial infarction, cp-MSCs injection, and
echocardiography
MI was induced as previously described [38]. Briefly, ani-
mals (n = 19) were anesthetized with an intraperitoneal in-
jection of xylazine (20 mg/kg) and ketamine (80 mg/kg).
After endotracheal intubation and ventilation (Harvard
Apparatus, Holliston, MA, USA), left anterior thoracot-
omy was performed, and the left anterior descending
coronary artery (LAD) was permanently ligated. A sham-
operated group (n = 11) was prepared in a similar manner
but without tightening the suture around the LAD.
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end-systolic volume (ESV), and end-diastolic volume
(EDV)—were determined by using Simpson’s method at
baseline and at 20 days post-MI by echocardiographic
imaging (Vevo 770, probe 30.0 MHz; VisualSonics, To-
ronto, ON, Canada).
At 21 days after MI, 30 μL of a 25% solution of Matri-
gel (BD Biosciences) in PBS containing either 105 cp-
MSCs (n = 11) or no cells (n = 8) was injected directly
into the border zone of the infarcts by using an
echocardiography-guided procedure. Mice received a
weekly injection for 3 weeks. Cardiac function parame-
ters were analyzed by echocardiogram on days 7, 15, 23,
and 39 after the first injection (Additional file 2). All
analyses were performed by a blinded investigator.
Construction of lentiviral vector containing Luc2 gene
and production of lentiviral particles
Lentiviral vector pMSCV.luc2.T2A.Puro was constructed
by cloning the luciferase 2 (Luc2) gene into the commercial
vector pCDH.MCS.T2A.Puro-MSCV (System Biosciences,
Mountain View, CA, USA). Luc2 gene was polymerase
chain reaction (PCR)-amplified from pGL4.50 plasmid
(Promega Corporation, Madison, WI, USA) by using
primers forward 5′-GCTAGCGAATTCGCCACCATGGA
AGATGCCAAAAAC-3′ including NheI restriction site
(underlined) and Kozac sequence (bold) and reverse 5′-
GCGGCCGCGGATCCCACGGCGATCTTGCCGCC-3′ in-
cluding NotI restriction site (underlined). PCR product
and pCDH.MCS.T2A.Puro-MSCV were both digested
with NheI and NotI and ligated by using T4 DNA ligase.
The final pMSCV.luc2.T2A.Puro plasmid was sequence-
verified. Pseudo-typed lentiviral particles encoding Luc2
reporter and puromycin resistance genes were produced
in HEK 293 T cells by co-transfection with accessory vec-
tors pΔ8.9 and pMD.G by using FuGene 6 transfection re-
agent (Roche) in accordance with the guidelines of the
manufacturer.
After a 24-hour incubation, culture media were re-
placed with DMEM-HG supplemented with 10% FBS.
Forty-eight and 72 hours after transfection, culture
media containing lentiviral particles were filtered (0.45
μm; Corning Life Sciences, Tewksbury MA, USA) and
concentrated by ultracentrifugation at 45,000 g for 2
hours at 4°C.
Transduction and cp-MSCs selection
cp-MSCs were transduced in the presence of polybrene
(8 μg/mL; Sigma-Aldrich). After 24 hours, culture medium
was replaced with the standard expansion medium. Ap-
proximately 48 hours after transduction, 0.2 μg/mL of
puromycin was added to the medium and changed every
other day. Cells were selected during 7 days and then ex-
panded for bioluminescence imaging assay.Bioluminescence imaging assay
For in vitro studies, transduced cells were plated in a
24-well plate at different concentrations: 104, 2 × 104, 4 ×
104, 6 × 104, 8 × 104, and 105 cells per well. D-Luciferin
(150 μg/mL) (Promega Corporation) was added to the cul-
ture medium in accordance with the guidelines of the
manufacturer. The culture plate was immediately posi-
tioned in the IVIS Lumina Imaging System (Caliper Life
Sciences, Hopkinton, MA, USA), and images were ac-
quired after a 10-second exposure period.
For in vivo studies, mice received D-Luciferin (150
mg/kg) intraperitoneally. Ten minutes after injection,
they were anesthetized with isoflurane gas and placed in
the IVIS Lumina Imaging System. Image acquisitions
were performed 1, 2, 3, and 5 days after the injection of
transduced cells. Exposure time never exceeded 5 mi-
nutes, to avoid false-negative results. In vitro and in vivo
results were analyzed with Living Image Software 3.2
software (Caliper Life Sciences).
Histology
At 40 days after the first injection, mice were sacrificed
and hearts were perfused with paraformaldehyde 4%.
Cardiac tissue was embedded in paraffin, and 5-μm sec-
tions were used to quantify the fibrotic scar by using Sir-
ius Red staining. Three measurements were made by
using sections from the apex toward the base of the
heart, and these values were averaged. Infarct area was
estimated by morphometry as a percentage of the total
area of the left ventricle by using Image-Pro Plus 7.0.1
software.
Quantitative reverse transcription-polymerase chain
reaction
Total RNA was isolated by using RNeasy Plus Mini kit
(Qiagen, Valencia, CA, USA) in accordance with the in-
structions of the manufacturer. Total RNA (500 ng) was
used for cDNA synthesis by using a High Capacity
cDNA Reverse Transcription kit (Applied Biosciences)
in accordance with the instructions of the manufac-
turer. The Human Cell Cycle RT2 profiler PCR array
(PAHS-020; SABiosciences, part of Qiagen) was used to
analyze the expression of genes related to cell cycle
regulation in cp-MSCs and cv-MSCs. The expression
of POU5F1 was also evaluated in these cells in a differ-
ent set of experiments. The Mouse Insulin Signaling
Pathway RT2 Profiler PCR array (PAMM-030; SA
Biosciences) was used to compare gene expression in
placebo- and cell-treated mouse hearts. A complete list
of the genes analyzed is presented in supplementary ta-
bles (Additional files 3 and 4). The relative quantities of
gene-specific mRNAs were calculated by using the
2−(ΔΔCt) method and web-based software available at the
SAbiosciences website.
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All values are expressed as mean ± standard error. Cardiac
function parameters were compared between groups by
using repeated measures one-way analysis of variance
(ANOVA) and, for time-dependent analysis, two-way
ANOVA. Comparisons between two groups were per-
formed by using the Student t test. Differences between
variables were considered significant when the P value
was not more than 0.05. The GraphPad Prism® software,
version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA),
was used for all statistical analyses.
Results
Placenta-derived MSC morphology, surface phenotype,
and differentiation
Two days after initial plating, both cp-MSCs and cv-MSCs
showed adherence to plastic and displayed fibroblast-like
morphology (n = 16), which was maintained for 15 pas-
sages (data not shown). Third-passage cells can be seen in
Additional file 5A and B. Primary cultures also contained
non-adherent cells, which were eliminated through media
change. Adherent, fibroblast-like cells derived from chori-
onic plate and chorionic villi in the primary culture reached
confluence in approximately 4 and 8 days, respectively.
We used flow cytometry to investigate the surface
phenotype of placenta-derived cells (Additional file 6). It
revealed that cp-MSCs (n = 5) and cv-MSCs (n = 4) were
positive for MSC-related markers CD90, CD73, and
CD105 as well as adhesion molecules CD54, CD44, and
CD166. Moreover, they showed very low expression of
hematopoietic surface markers, such as CD45, CD34,
CD117, CD14, CD19, and HLA-DR and endothelial
markers CD133 and CD31. The phenotype observed in
cp-MSCs and cv-MSCs was consistent with the profile of
human bone marrow-derived MSCs. We found no signifi-
cant differences in the expression of mesenchymal, endo-
thelial, or hematopoietic molecules between cp-MSCs and
cv-MSCs (Figure 1D).
To evaluate multipotency of cp-MSCs and cv-MSCs,
we differentiated them into adipocytes, osteoblasts, and
chondroblasts. After adipogenic differentiation, cp-MSCs
(Figure 1Eii) and cv-MSCs (Figure 1Eiv) accumulated
lipid-rich vacuoles, stained in red by Oil Red O. Control
cultures were maintained with expansion medium and,
at the end of protocol, did not show lipid accumulation
(Figure 1Ei and iii). After osteogenic differentiation, cp-
MSCs (Figure 1Fii) and cv-MSCs (Figure 1Fiv) showed cal-
cium deposits in the extracellular matrix, stained in red by
Alizarin Red, which characterizes matrix mineralization.
Moreover, no spontaneous differentiation was observed in
control cultures (Figure 1Fi and iii).
When cp-MSCs and cv-MSCs were cultured in
micromass-forming conditions, the formation of a single
aggregate was observed after 24 hours in both inducedand non-induced cells. After Alcian Blue and Nuclear
Fast Red staining, paraffin sections of induced cp-MSCs
(Figure 1Gii) and cv-MSCs (Figure 1Giv) showed synthe-
sis of proteoglycans in blue, which are characteristic of
the cartilaginous matrix, and nuclear staining in red.
Paraffin sections of non-induced cp-MSCs and cv-MSCs
showed no proteoglycan staining (Figures 1Gi and iii).
Clonogenic properties, growth kinetics, and chromosomal
stability of placenta-derived MSCs
To analyze cell clonogenic potential, CFU-F assays were
performed in single-cell suspensions from chorionic
plate (n = 6) and chorionic villi (n = 5) preparations.
Both of them were able to generate CFU-F (Figure 1A).
Colonies stained with Giemsa solution were quantified.
Chorionic plate- and chorionic villi-derived cells yielded
78.5 ± 10.1 and 31.4 ± 5.2 colonies per 105 plated cells,
respectively (P = 0.0015) (Figure 1B). Thus, cp-MSCs
were at least two times more efficient in generating
clones than cv-MSCs.
When cultured in expansion medium, third-passage
cp-MSCs and cv-MSCs plated in 35-mm dishes for PDT
assay reached 100% confluence in approximately 8 days.
With daily monitoring of cellular growth, we were able
to show that the proliferation rate of both cell types
followed an exponential curve (Additional file 7A).
The time required to double the cell population was
estimated by calculating the inverse of the angular coef-
ficient obtained from the linear regression formed
after applying a base 2 logarithm in the cells per milli-
meter squared axis (Additional file 7B). No statistical dif-
ference was observed between cp-MSCs and cv-MSCs
PDT (1.7 ± 0.1 versus 2.3 ± 0.5, respectively; P = 0.4)
(Additional file 7C). However, there is a clear tendency to-
ward a faster growth of cp-MSCs compared with cv-MSCs.
Karyotype analysis was performed on GTG-banded
metaphases from cp-MSCs (n = 3) and cv-MSCs (n = 3).
All 20 metaphases that were analyzed from each sample
were normal (karyotype: 46, XY) (Figure 1C).
In addition, expression of isoform 1 of the POU5F1
gene was detected in both cell types (Additional file 8)
after excluding the artifactual detection of the POU5F1B
gene or the presence of pseudogenes (Additional file 8C).
Nonetheless, levels of POU5F1 were much lower in
placenta-derived cells than in human embryonic stem cells
(data not shown).
Distinct transcript profile of cell cycle-related genes in
cv- and cp-MSCs
Quantitative reverse transcription-polymerase chain re-
action arrays were used to measure differences in the
transcript levels of genes related to cell cycle regulation.
We identified a difference of at least twofold in the ex-
pression of 15 cell cycle-related genes (Figures 1H and
Figure 1 Characterization of placenta-derived cells. (A) Fibroblast colony-forming units (CFU-F) assay. Freshly isolated cells derived from (i)
chorionic plate (cp) and (ii) chorionic villi (cv) were cultured in CFU-F forming conditions and stained with Giemsa. Black arrows indicate colonies.
(B) The quantity of clones formed by cp-derived cells (78.5 ± 10.1) and cv-derived cells (31.4 ± 5.2) was compared (*P = 0.0015). (C) Karyotype
analysis of cp- and cv-mesenchymal stem cells (MSCs) showing a 46, XY karyotype in both cases. (D) Flow cytometry analysis. Graph shows
the percentage of positive cells for each surface marker in cp-MSCs (striped) and cv-MSCs (white). Expression of mesenchymal markers and adhe-
sion molecules was high, while low expression of hematopoietic and endothelial markers was found. (E) Oil Red O staining after adipogenic
differentiation. Cytoplasmic lipid droplets were observed in the induced (ii) cp-MSCs and (iv) cv-MSCs but were not present in the non-induced
cultures (i and iii). White arrows indicate lipid droplets within the cytoplasm. (F) Alizarin Red staining after osteogenic differentiation. Calcium
deposits in the extracellular matrix were observed in the induced (ii) cp-MSCs and (iv) cv-MSCs but were not present in the non-induced cultures
(i and iii). Inserts in (E) and (F) show images in higher magnification. (G) Analysis of 3-week cultured pellets after chondrogenic differentiation.
The micromass was stained with Alcian Blue. Nuclei were counterstained with Nuclear Fast Red. Proteoglycans, stained in blue, were observed
in the induced (ii) cp-MSCs and (iv) cv-MSCs. Non-induced cultures (i and iii) did not present proteoglycan staining. (H) Quantitative reverse
transcription-polymerase chain reaction (RT-PCR) array for cell cycle-related genes. Results are shown as fold changes in expression of cp-MSCs
(stripped bars) when compared with cv-MSCs (white bar). All genes that were at least twofold up- or downregulated in cp-MSCs when compared
with cv-MSCs are shown. Expression of BRCA2 and CCNF was significantly higher in cp-MSCs (*P <0.05).
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ference in the expression of BRCA2 (6.85-fold, P = 0.02),
which is critical for the control of homologous recombin-
ation and DNA damage repair, and CCNF (2.42-fold,
P = 0.03) in cp-MSCs when compared with cv-MSCs.Myocardial infarction and therapy with cp-MSCs
Since cp-MSCs had a greater clonogenic potential and
expressed more genes related to cell cycle progression
and stability, we considered them a preferable source for
cell therapy in our model. At 20 days after MI, before
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presented a significant decrease in EF and increase in
ESV and EDV when compared with the sham group
(Table 1). No statistical difference was observed in car-
diac function between mice in the cp-MSCs or placebo
group at this time point (Table 1).
EF and ESV were significantly improved in the cp-
MSC group when compared with placebo at 15 and 39
days after cell or vehicle injection (Table 1 and Figure 2A
and C). Cell therapy had no significant effect on EDV
when comparing cell-treated and placebo groups (Table 1
and Figure 2B).
Determination of cell engraftment by bioluminescence
cp-MSCs were transduced with a lentiviral vector con-
taining the luciferase 2 and puromycin resistance genes
under the control of MSCV promoter. Imaging of a dilu-
tion series containing 1 to 10 × 104 cells in vitro showed
a strong linear correlation between photon emission and
cell number (R2 = 0.95) (Additional file 10A and B), in-
dicating that bioluminescence offers a reliable estimation
of cell numbers.
To determine the distribution of Luc2-transduced cp-
MSCs after intramyocardial injection in sham (n = 3) or










−22 57.5 ± 3.6 59.5 ± 5.6 59.3 ± 3.6
−1 50.2 ± 1.7 28.7 ± 2.1b 27.4 ± 2.6b
7 49.8 ± 2.4 34.3 ± 3.1 26.4 ± 3.0
15 50.9 ± 2.6 33.8 ± 1.9 22.9 ± 2.4c
23 48.3 ± 1.8 31.2 ± 3.1 24.6 ± 2.6
39 46.2 ± 2.6 33.8 ± 2.3 22.2 ± 2.1d
End-systolic volume, μL
−22 24.4 ± 3.9 23.3 ± 7.4 17.7 ± 3.8
−1 31.3 ± 2.3 61.4 ± 4.7b 67.2 ± 5.5b
7 31.6 ± 2.7 55.5 ± 6.2 62.4 ± 7.3
15 34.35 ± 3.4 60.4 ± 5.3 75.8 ± 6.8c
23 34.5 ± 2.2 64.6 ± 6.5 77.2 ± 6.4
39 34.7 ± 3.5 58.3 ± 7.9 80.7 ± 8.5c
End-diastolic volume, μL
−22 56.3 ± 4,9 54.8 ± 9.5 53.8 ± 8.5
−1 62.3 ± 3.4 84.2 ± 4.3b 92.0 ± 4.8b
7 62.6 ± 4.2 82.5 ± 5.6 90.9 ± 7.9
15 68.6 ± 4.2 90.6 ± 6.9 98.0 ± 6.9
23 67.2 ± 3.9 91.8 ± 6.1 102.6 ± 7.3
39 63.6 ± 4.2 89.9 ± 9.2 104.3 ± 9.6
aDay −22 shows baseline values (before myocardial infarction) for all groups.
Day −1 shows data before treatment with either chorionic plate mesenchymal
stem cells (cp-MSCs) or placebo. bP <0.05 compared with Sham. cP <0.05,
dP <0.01 comparing cp-MSCs versus placebo.performed 10 minutes after intraperitoneal administra-
tion of D-Luciferin. Luciferase expression was monitored
in vivo by real-time imaging of the whole body, and this
signal was superimposed to a light photograph to pro-
vide an anatomical reference. Repeated analyses on the
same animal at different time points allowed the study
of the biodistribution and engraftment of transduced cp-
MSCs in healthy and infarcted hearts.
In sham and infarcted mice, cells were detected in only
the thoracic region. In both groups, after the first cp-
MSCs injection, most of the signal was lost after the
third day, suggesting that cells did not engraft perman-
ently in the heart (Figure 3). For quantification purposes,
the signal in the following days was normalized to
the signal at 24 hours after injection. No statistical dif-
ference was observed between sham and infarcted ani-
mals (Figure 3C). Moreover, after the second and third
cp-MSCs injections, cells remained for even less time in
the heart since the signal was predominantly absent only
24 hours after injection in both sham and infarcted mice
(Figure 3). These data indicate that permanent engraft-
ment is not required for the improvement of cardiac
function in cp-MSC therapy.
Quantification of infarct area
The absence of cell engraftment in bioluminescence exper-
iments suggested that direct regeneration of cardiac muscle
was likely not involved in the improvement of function.
The fact that no difference was found between infarct areas
in placebo- and cell-treated groups further supports this
notion. Sirius red staining showed that 14.8% ± 2.6% and
10.7% ± 1.2% of the left ventricle were infarcted in the pla-
cebo and cp-MSCs groups, respectively (Figure 4).
Insulin signaling pathway regulation
Transcript levels of genes associated with the insulin sig-
naling pathway were evaluated 39 days after therapy in
the heart of mice treated with either cp-MSCs (n = 3) or
placebo (n = 3). No differences were found in the major-
ity of the transcripts analyzed in these hearts (Additional
file 11). Among those transcripts in which statistical dif-
ferences were found between cell-treated and placebo
groups, none of them had a variation of more than two-
fold, suggesting that these results might not be biologic-
ally relevant (Additional file 11).
Discussion
The application of MSCs in cell therapy and regenerative
medicine is promising, and their beneficial effects have
been demonstrated in several murine disease models, such
as stroke [39], chronic airway inflammation [40], and
acute MI [41-44]. However, to the best of our knowledge,
the effects of human placenta MSC transplantation have
not been evaluated in a murine model of healed MI.
Figure 2 Assessment of cardiac function in infarcted mouse
hearts transplanted with chorionic plate mesenchymal stem
cells (cp-MSCs) or placebo. Echocardiography was performed
before (corresponding to day −22 of treatment) and 20 days after
myocardial infarction (corresponding to day −1 of treatment) to
obtain baseline values in mice receiving cp-MSCs (squares) or
placebo (triangles). Analysis of (A) ejection fraction, (B) end-diastolic
volume, and (C) end-systolic volume was performed every 7 days
after each cell or placebo injection. Day 7 corresponds to 7 days
after the first injection, day 15 corresponds to 7 days after the
second injection, and day 23 corresponds to 7 days after the third
injection. Animals were followed up to 39 days after the first
injection. *P <0.05 and **P <0.01 when comparing cp-MSC with
placebo group at each time point. Sham-operated mice (circles),
which did not undergo left anterior descending coronary artery
occlusion, are shown as controls to indicate normal values for
each parameter.
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the preferable source of placenta MSCs. Since these cells
can be isolated from two different regions, the chorionic
plate [23-26] or the chorionic villi [13-15,20], a full
characterization of MSCs derived from these two regions
was performed. At first, one might think that cp-MSCs
and cv-MSCs are equivalent given that the chorionic villi
arise from the chorionic plate during human develop-
ment. Even though these cells are quite similar in several
aspects, the difference in their clonogenic potential
seemed important to us. Since the capacity of generating
clones is related to the amount of stem cells in the start-
ing sample, our results suggest that stem cells are
present in higher numbers in the chorionic plate.
In addition, key cell cycle regulators were also differen-
tially expressed in cp-MSCs. BRCA2 is a positive regulator
of homologous recombination through its interaction with
RAD51 recombinase [45]. It acts recruiting RAD51 to
double-strand breaks and initiating DNA repair, which is
crucial for the maintenance of genome integrity [45]. Im-
portantly, RAD51 was increased 2.22-fold in cp-MSCs, al-
though this result did not reach statistical significance.
Cyclin F (CCNF) was also significantly upregulated in cp-
MSCs. This molecule drives cell cycle progression and also
plays a role in DNA repair and genome integrity [46].
Moreover, cyclin F seems to be particularly important for
the placenta since its deletion is lethal during embryonic
development because of failure in yolk sac and chorio-
allantoic placentation [47].
Given their superior clonogenic potential and in-
creased expression of genome integrity regulators, we se-
lected cp-MSCs as our candidates for cell therapy in a
murine model of MI. In accordance with a recent state-
ment from the American Heart Association [48], our
model fulfilled functional criteria of dilated cardiomyop-
athy and heart failure, as demonstrated by the increase
in EDV and reduction in EF before treatment with
Figure 3 In vivo imaging of transduced chorionic plate mesenchymal stem cell (cp-MSCs) administered by intramyocardial injection in
sham and infarcted mice. Bioluminescence imaging was repeated daily. After the first injection, the signal was located in a region anatomically
compatible with the heart in sham (A) and infarcted (B) mice injected with cp-MSCs. After the second and third injections, the luminescent signal
was observed for only 1 or 2 days in these animals. In addition, the signal intensity was lower than after the first injection. The scales represent
luminescence intensity in radiance units, in which red and blue are the most and least intense, respectively. (C) Signal quantification in sham
(circles) and infarcted (squares) groups after the first injection of cp-MSCs. Quantification of the bioluminescent signal showed no statistical
difference in the engraftment period for both groups.
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healed by using three weekly intramyocardial injections
of either cp-MSCs or placebo. Evidence from other
disease models demonstrates that repeated injections
of MSCs are superior to a single injection [49,50], which
is expected in any therapeutic approach. The difficulty of
performing repeated injections by using an intramyocardialdelivery route is the need for repeated thoracotomies,
which increase mortality substantially. To overcome this
issue, our cell delivery procedure did not require thoracot-
omy since it was guided by echocardiography and cp-
MSCs were successfully injected, as demonstrated by the
bioluminescence data. Forty days after the first injection,
cell therapy with cp-MSCs led to an improvement in
Figure 4 Impact of chorionic plate mesenchymal stem cell (cp-MSC) injection on infarct area. (A) Representative example of scar
formation 39 days after the first injection in mice treated with cp-MSCs or placebo. Macroscopic infarct area was assessed in each group by Sirius
Red staining. Fibrous scar tissue is shown in red, whereas myocardium is stained in yellow. Serial sections of the same heart are shown from
apex (i) to base (iii). (B) Infarct area (red-stained tissue) was quantified as a percentage of total area. The graph shows an average of infarct area
calculated from the three serial sections. No statistical difference was observed in the scar formation between cp-MSC and placebo groups.
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creased, but did not influence cardiac remodeling, as dila-
tion was not diminished.
To investigate whether the cells remained in the myo-
cardium after injection, we performed cell tracking ex-
periments by bioluminescence. We considered this to be
an ideal approach since our data demonstrated a strong
correlation between the bioluminescent signal and the
amount of cells. In addition, since luciferin metabolism
requires ATP, only living cells expressing luciferase are
capable of producing signal. Our data demonstrated that
the presence of injury did not influence the amount of
time that cp-MSCs remained in cardiac tissue and that
engraftment was not permanent. In fact, cells disap-
peared quite rapidly and did not migrate to other organs.
Moreover, cells remained even less time in the tissue
after the second and third injections. Engraftment has
become a critical issue for cell-based therapies as many
groups have demonstrated that the majority of the
injected cells are lost after very few days [51]. In our
model, one could argue that cell loss could be due sim-
ply to immune rejection of cp-MSCs in a xenogeneic
transplantation setting, especially after the second and
third injections. There are some points that need to be
made in this regard. The immunomodulatory properties
of MSCs are well known [1,52], even though most
in vivo models focus on allogeneic, not xenogeneic, sce-
narios and, in the case of human MSCs, on in vitro, ra-
ther than in vivo, experiments. However, a number of
articles in different disease models show that xenotrans-
plantation of MSCs has a therapeutic effect (for a review
on this subject, see [53]). Lastly, the fact is that, in asyngeneic, allogeneic, or xenogeneic setting, permanent
engraftment of transplanted cells does not occur [51,54].
The absence of bioluminescent signal indicates that few
cells, if any, remained in the myocardium, suggesting
that regeneration due to transdifferentiation of cp-MSCs
was not the primary mechanism involved in the im-
provement of cardiac function and favoring the “para-
crine hypothesis”.
The paracrine hypothesis proposes that the benefits
promoted by cell therapy are due to the release of sol-
uble factors that induce angiogenesis and exert cardio-
protective effects [55,56]. The insulin signaling pathway
has been implicated as an important contributor to this
effect [55,57]. However, our results show that the effect
of MSC therapy does not seem to be mediated by the in-
sulin signaling pathway, as we did not find substantial
changes in genes related to this pathway when compar-
ing cell- and placebo-treated hearts. Nonetheless, since
our analysis was performed 39 days after treatment, we
cannot exclude that this pathway was modulated at a
different time point. In addition, the number of analyzed
animals in each group was small (n = 3), and although
quantitative PCR arrays are very sensitive, subtle differ-
ences in gene expression could be masked.
One of the major issues in recognizing that the mech-
anism of action using MSCs might be paracrine resides
in the fact that one could simply administer soluble fac-
tors and reach the same result [55]. However, aside from
the many caveats of this type of therapy, such as protein
stability and pharmacokinetics, soluble factors lack a
property that we consider to be crucial: a sensor system
that responds and is modulated by the environment.
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approaches and, although it may be one of its strongest
suits, it is also responsible for its mechanistic elusiveness.
The same cell might respond in several different ways, de-
pending on the stimuli it receives from a given tissue; thus,
we might never be able to fully understand the crosstalk
that takes place in this scenario. On the other hand, des-
pite the mechanistic discussion that has been dominating
the field in basic research [58,59], cell therapy with MSCs
has proven to be safe in the clinical setting [52,60], and
data of phase II trials in cardiovascular diseases should be-
come available in the next years.
Conclusions
We have extensively characterized MSCs derived from
the two placenta regions commonly used for cell isola-
tion, showing many similarities but some important dif-
ferences that point to the chorionic plate as a preferable
source for placenta MSCs. Moreover, we demonstrate
that cp-MSCs improve cardiac function after MI, an ef-
fect that was not dependent on permanent cell engraft-
ment and did not involve modulation of the insulin
signaling pathway. Hence, the placenta is a suitable
source of MSCs for allogeneic cell therapy and has the
further advantage of being a virtually inexhaustible tissue
that can be easily obtained without invasive procedures
and cell-banked.
Additional files
Additional file 1: Methods of isolation for mesenchymal stem cells
(MSCs) from different regions of the human term placenta
[13-20,22,23,25,26,61-66].
Additional file 2: Experimental protocol. Numbers represent days
before or after the first injection of chorionic plate mesenchymal stem
cells (cp-MSCs) or placebo (therapy at day 0). ECG, electrocardiogram;
ECHO, echocardiogram; Histo, histology.
Additional file 3: Genes analyzed by the cell cycle pathway
polymerase chain reaction (PCR) array.
Additional file 4: Genes analyzed by the insulin signaling pathway
polymerase chain reaction (PCR) array.
Additional file 5: Morphology of placenta-derived mesenchymal
stem cells (MSCs) in phase contrast microscopy. Third-passage MSCs
from (A) chorionic plate and (B) chorionic villi presented fibroblast-like
cell morphology.
Additional file 6: Flow cytometry analysis. Representative flow
cytometry histograms of surface molecule expression in chorionic plate
mesenchymal stem cells (cp-MSCs) (A) and chorionic villi mesenchymal
stem cells (cv-MSCs) (B). The fluorescence intensity for each molecule is
shown in the x-axis. Isotype controls are represented by the light gray curve.
Positive events were calculated by subtracting the events obtained using
the primary antibody from the isotype control. The average percentage of
positive events ± standard error of the mean (SEM) is shown in the upper
right corner of each histogram; 7 aminoactinomyocin D (7AAD) (green) was
used to exclude dead cells.
Additional file 7: Population doubling time (PDT) assay. (A) Daily
quantification of cp-MSCs (circles and full line) and cv-MSCs (squares and
dashed line) showed an exponential growth. (B) The exponential curves
shown in (A) were transformed by using a log2 scale in the y-axis. PDTwas calculated by performing linear regression and using the inverse
of the slope (or angular coefficient) as an estimate of duplication time.
(C) PDT values in days from independent experiments are shown for
cp-MSCs and cv-MSCs. Above the bars, mean ± standard error of the
mean (SEM) values of PDT are indicated for each cell type.
Additional file 8: Expression of POU5F1 (NM_002701.4) in placenta-
derived cells. (A) Reverse transcription-polymerase chain reaction
(RT-PCR) detection of transcripts POU5F1 (136 bp) and GAPDH (162 bp)
in chorionic plate mesenchymal stem cells (cp-MSCs) (lanes 1 and 3),
chorionic villi mesenchymal stem cells (cv-MSCs) (lanes 2 and 4), and
human embryonic stem cells (lane 5). Samples in lanes 1 and 2 were
derived from chorionic plate and chorionic villi obtained from the same
placenta. The same is true for samples in lanes 3 and 4. (B) Since the
expression of POU5F1 in adult MSCs is controversial [67,68], we designed
primers that recognize transcript variant 1 of POU5F1 but that do not
recognize transcript variants 2 and 3, which are not expressed in pluripotent
stem cells. Moreover, to differentiate POU5F1 from POU5F1B (NM_001159542.1),
which is a different gene not related to pluripotency, both primers
have a mismatch in the last nucleotide (underlined), which prevents
amplification of POU5F1B. (C) To further confirm our results, PCR
products were sequenced and compared with POU5F1 transcript
variant 1, POU5F1B, and pseudogenes 3 and 4. Light gray bases show
similarities between sequences. Black bases represent mismatches.
The PCR product sequence (28V_F) shows 100% similarity only to
POU5F1 transcript variant 1. Thus, sequence alignment analysis revealed
that adult MSCs express transcript variant 1 of POU5F1. Nevertheless,
it is likely that other transcript variants (2 and 3), POU5F1B and/or
pseudogenes are also expressed. We immunostained placenta-derived
MSCs and detected the presence of nuclear OCT4 protein (data not
shown). However, OCT4 (product of POU5F1) has 96% homology to
OCT4B (product of POU5F1B) [68], making it impossible to discriminate
between them with commercially available antibodies. Finally, it is
difficult to speculate which function POU5F1 might have in these cells
since they are not pluripotent.
Additional file 9: Expression of cell cycle-related genes in chorionic
plate mesenchymal stem cells (cp-MSCs) compared with chorionic
villi mesenchymal stem cells (cv-MSCs). (A) Heat map shows log2
(fold-change) of downregulated (green) and upregulated (red) genes in
cp-MSCs when compared with cv-MSCs. (B) Table identifies and specifies
mean fold-change values for each of the genes analyzed by quantitative
reverse transcription-polymerase chain reaction (qRT-PCR). Targets with at
least twofold upregulation are shown in red, whereas targets with at least
twofold downregulation are shown in blue. Full names and accession
numbers for all the genes can be found in Additional file 3.
Additional file 10: Luciferase 2 expression in transduced chorionic
plate mesenchymal stem cells (cp-MSCs). (A) Bioluminescence
imaging of cp-MSCs in vitro shows higher luminescent signal with the
increase of cell density. On the right, a scale of the luminescent signal is
shown using radiance units. (B) Graph shows a linear correlation between
cell numbers and the emitted radiance (R2 = 0.95).
Additional file 11: Expression of insulin signaling pathway-related
genes in the hearts of chorionic plate mesenchymal stem cell
(cpMSC)-treated compared with placebo-treated mice. (A) Heat map
shows log2 (fold-change) of downregulated (green) and upregulated
(red) genes in cp-MSCs when compared with placebo-treated mice.
(B) Table identifies and specifies mean fold-change values for each of the
genes analyzed by quantitative reverse transcription-polymerase chain
reaction (qRT-PCR). The vast majority of the genes had less than twofold
difference between experimental groups. The four cases with more
than twofold difference (Cfd, Gck, Irs2, and Nos2) did not reach statistical
significance. Full names and accession numbers for all the genes can be
found in Additional file 4.
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